In yesterday’s Wall Street session, DexCom Inc. (NASDAQ:DXCM) shares traded at $130.60, down -0.04% from the previous session.
As of this writing, 22 analysts cover DexCom Inc. (NASDAQ:DXCM). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $152.00 and a low of $115.00, we find $147.50. Given the previous closing price of $130.65, this indicates a potential upside of 12.9 percent. DXCM stock price is now 4.54% away from the 50-day moving average and 13.21% away from the 200-day moving average. The market capitalization of the company currently stands at $50.64B.
There are 3 analysts who have given it a hold rating, whereas 17 have given it a buy rating. Brokers who have rated the stock have averaged $142.51 as their price target over the next twelve months.
In other news, Pacelli Steven Robert, EVP Managing Director Dexcom V sold 5,031 shares of the company’s stock on Jul 14. The stock was sold for $684,216 at an average price of $136.00. Upon completion of the transaction, the EVP Managing Director Dexcom V now directly owns 126,831 shares in the company, valued at $16.56 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 10, EVP Operations Regan Barry J. sold 1,989 shares of the business’s stock. A total of $254,691 was realized by selling the stock at an average price of $128.05. This leaves the insider owning 66,269 shares of the company worth $8.65 million. Insiders disposed of 467,031 shares of company stock worth roughly $60.99 million over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in DXCM stock. A new stake in DexCom Inc. shares was purchased by REDMILE GROUP, LLC during the first quarter worth $43,888,000. QUBE RESEARCH & TECHNOLOGIES LTD invested $28,154,000 in shares of DXCM during the first quarter. In the first quarter, ADAMS DIVERSIFIED EQUITY FUND, INC. acquired a new stake in DexCom Inc. valued at approximately $25,461,000. COVEA FINANCE acquired a new stake in DXCM for approximately $19,969,000. SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC purchased a new stake in DXCM valued at around $16,513,000 in the second quarter. In total, there are 1,324 active investors with 98.80% ownership of the company’s stock.
Friday morning saw DexCom Inc. (NASDAQ: DXCM) opened at $130.98. During the past 12 months, DexCom Inc. has had a low of $77.51 and a high of $138.92. As of last week, the company has a debt-to-equity ratio of 0.91, a current ratio of 2.00, and a quick ratio of 1.80.
According to the Medical Devices Company, earnings per share came in at $0.17, beating analysts’ expectations of $0.15 by 0.02. This compares to $0.23 EPS in the same period last year. The net profit margin was 9.70% and return on equity was 13.90% for DXCM. The company reported revenue of $741.5 million for the quarter, compared to $628.8 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 17.92 percent. For the current quarter, analysts expect DXCM to generate $841.62M in revenue.
DexCom Inc.(DXCM) Company Profile
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices for specific and permitted use cases, including non-medical device applications, medical device data analysis, integrated continuous glucose monitoring systems (iCGM) secondary display alarms, active patient monitoring, and treatment decisions; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
